

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**UTILITY APPLICATION AND FEE TRANSMITTAL (1.53 (b))**

ASSISTANT COMMISSIONER FOR PATENTS  
Box Patent Application  
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of

All Inventor(s)

- including Address(es): (1) Klaus Mosbach  
Lackalanga 31, S-244 94 Furulund, SWEDEN
- (2) Georg Vlatakis  
Foundation for Research & Technology  
Institute of Molecular Biology and Biotechnology  
GR-711 70 Heraklion, Crete, GREECE
- (3) Lars I. Andersson  
Skogsvagen 45, S-241 31 Eslov, SWEDEN
- (4) Ralf Muller  
Gorch-Foch Strasse 25  
D-2359 Henstedt-Ulzburg 3, GERMANY

For: ARTIFICIAL ANTIBODIES, METHOD OF PRODUCING THE SAME  
AND USE THEREOF

Enclosed are:

[ X ] 16 Pages of specification, 1 page of Abstract, 4 pages of claims

[ X ] 1 Sheet of Drawing [X] formal [ ] informal

[ X ] 8 Pages of Declaration and Power of Attorney

[ ] Unsigned

[ ] Newly Executed

[X] Copy from prior application.

[ ] Deletion of inventors including Signed Statement under 37 C.F.R. § 1.63(d)(2).

- ☒ Incorporation by Reference: The entire disclosure of the prior application, from which a copy of the combined declaration and power of attorney is supplied herein, is considered as being part of the disclosure of the accompanying application and is incorporated herein by reference.
- ☐ Microfiche Computer Program (Appendix)
- ☐ \_\_\_\_ page(s) of Sequence Listing
- ☐ computer readable disk containing Sequence Listing
- ☐ Statement under 37 C.F.R. § 1.821(f) that computer and paper copies of the Sequence Listing are the same
- ☐ Assignment Papers (assignment cover sheet and assignment documents)
- ☐ A check in the amount of \$40.00 for recording the Assignment.
- ☐ Assignment papers filed in parent application Serial No. \_\_\_\_\_.
- ☐ Certification of chain of title pursuant to 37 C.F.R. § 3.73(b).
- ☒ Foreign Priority data as claimed by applicant – PCT/SE93/00960 filed November 11, 1993. Foreign priority is also claimed under 35 U.S.C. § 119 from Swedish Patent Application No. 9203435-4 filed November 11, 1992.
- ☐ Priority document(s) will be submitted at a later date.
- ☐ Priority document(s) is/are submitted herewith.
- ☐ Information Disclosure Statement
- ☐ Copies of \_\_\_\_ cited references
- ☒ Return receipt postcard (MPEP 503)
- ☒ This is a ☒ continuation ☐ divisional ☐ continuation-in-part (C-I-P) of prior application Serial No. 08/433,514 filed December 7, 1995.

- ☒ Cancel in this application original claims 1-26 of the parent application before calculating the filing fee.
- ☒ A Preliminary Amendment is enclosed providing claims 27-35. (Claims added by this Amendment have been properly numbered consecutively beginning with the number following the highest numbered original claim in the prior application.
- ☒ The status of the parent application is as follows:
- ☒ A Petition For Extension of Time and a Fee therefor has been or is being filed in the parent application to extend the term for action in the parent application until May 6, 1999.
- ☐ A copy of the Petition for Extension of Time in the co-pending parent application is attached.
- ☐ No Petition For Extension of Time and Fee is necessary in the co-pending parent application.
- ☐ Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.
- ☐ Transfer the drawing(s) from the parent application to this application.
- ☒ Amend the specification by inserting before the first line the sentence:
- This is a ☒ continuation ☐ divisional ☐ continuation-in-part of co-pending application Serial No. 08/433,514; Filed December 7, 1995.--

I. CALCULATION OF APPLICATION FEE


	Number Filed		Number Extra	Rate	Basic Fee \$760.00/380.00
Total Claims	9	-20=	x	\$18.00/9.00	\$0.00
Independent Claims	1	- 3=	x	\$78.00/34.00	\$0.00
Multiple Dependent Claims	<input type="checkbox"/> Yes Additional fee			=	\$260.00/130.00 \$0.00
	<input checked="" type="checkbox"/> No Additional fee			=	
Total:					\$760.00

- ☐ A statement claiming small entity status is attached or has been filed in the above-identified parent application and its benefit under 37 C.F.R. § 1.28(a) is hereby claimed. Reduced fees under 37 C.F.R. § 1.9(F) (50% of total) paid herewith \$\_\_\_\_\_.
- ☐ A check in the amount of \$\_\_\_\_\_ in payment of the application filing fees is attached.
- ☒ Charge Fee(s) to Deposit Account No. 13-4503. Order No. 2324-7028US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for filing this application, or credit any overpayment to Deposit Account No. 13-4503, Order No. 2324-7028US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: May 6, 1999

By: 

J. Steven Rutt  
Registration No. 40,153  
(202) 857-7887 Telephone  
(202) 857-7929 Facsimile

CORRESPONDENCE ADDRESS:

Morgan & Finnegan L.L.P.  
345 Park Avenue  
New York, New York 10154  
Tel: (212) 758-4800 - (202) 758-6849 Facsimile

FORM: UTL-TRAN.NY - Rev. 12/07/97

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: MOSBACH et al.

Serial No.: Continuation of 08/433,514 filed December 7, 1995

Filed: May 6, 1999

For: ARTIFICIAL ANTIBODIES, METHOD OF  
PRODUCING THE SAME AND USE THEREOF

**PRELIMINARY AMENDMENT**

Assistant Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

This Preliminary Amendment is being filed concurrently with the above-referenced continuation application. Please amend the above-identified continuation application prior to calculating the filing fee and examination on the merits, as follows:

**IN THE CLAIMS:**

Please cancel claims 1-26 without prejudice.

Please insert the following new claims 27-35:

-- 27. The artificial antibodies comprising a crosslinked polymer prepared by molecular imprint polymerization and having specific binding sites, wherein said artificial antibodies have a particle size of less than about five microns.

28. The artificial antibodies according to claim 27, wherein said particle size is between about 10 nm and 100 nm.

29. The artificial antibodies according to claim 27, wherein said specific binding sites are specific for drug molecules.

30. The artificial antibodies according to claim 29, wherein said drug molecule is theophylline.

31. The artificial antibodies according to claim 29, wherein said drug molecule is a benzodiazepine drug.

32. The artificial antibodies according to claim 29, wherein said drug molecule is diazepam.

33. The artificial antibodies according to claim 29, wherein said drug molecule has a narrow therapeutic index.

34. A method for assaying a drug molecule in serum, said method comprising the

combination of steps:

providing a fluid sample with said drug molecule,  
adding a known amount of labeled molecule to said sample,  
contacting said sample with artificial antibodies according to claim 27, whereby said  
drug molecule and said labeled molecule are competitively bound to said artificial antibodies,  
determining the amount of said labeled molecule unbound in said sample or bound  
to said artificial antibody.

35. The method according to claim 34, wherein said label is selected from the group  
consisting of radioligands, enzymes, biotin, steroids, fluorochrome, electrochemiluminescent  
compounds, and gold. —

REMARKS

Claims 1-26 have been cancelled without prejudice. New claims 27-35 have been added and are not believed to constitute new matter. Examination on the merits and allowance of this application are respectfully requested.

Respectfully submitted,

MORGAN & FINNEGAN L.L.P.

Date: May 6, 1999

By: 

J. Steven Rutt

Reg. No. 40,153

Tel: (202) 857-7887

Fax: (202) 857-7929

CORRESPONDENCE ADDRESS:  
Morgan & Finnegan, L.L.P.  
345 Park Avenue  
New York, New York 10154  
Tel: (212) 758-4800  
Fax: (212) 758-6849



ARTIFICIAL ANTIBODIES, METHOD OF PRODUCING THE SAME AND  
USE THEREOF

The present invention concerns artificial antibodies,  
5 a method for producing the artificial antibodies, a method  
for determination of an organic molecule in a fluid  
sample, a method for separation or isolation of an organic  
molecule and use of the latter methods in immunoassays as  
well as a method of therapy or diagnostics.

10 Antibodies are used in several areas, such as thera-  
py, immunoaffinity, purification and in particular in  
immunoassays. As to the latter aspect the corresponding  
antigens can either be small or large molecules.

Antibodies are normally produced by immunising ani-  
15 mals with the corresponding antigen leading to polyclonal  
antibodies, or by using fused cells (B cells) allowing the  
obtained cell lines to produce monoclonal antibodies.

Recent efforts in obtaining other biologically deriv-  
ed antibodies or at least antibody-like compounds involve  
20 recombinant techniques applied to bacteria or plants.

Antibodies can be raised against most compounds; they  
are versatile reagents employed in numerous applica-  
tions<sup>1-5</sup>, ranging from basic research to clinical analy-  
sis. However, being bio-macromolecules they require care-  
25 ful handling and their production is costly<sup>5</sup>.

A potentially useful alternative would be the produc-  
tion of non-biologically derived antibody mimics or arti-  
ficial antibodies, such as polymer structures that are  
similar to biological antibodies in binding and recogni-  
30 sing antigens.

The inherent advantages of such systems would be that  
the need for animal sources is obliterated, and that anti-  
body mimics can be obtained for cases where it is diffi-  
cult or impossible to raise antibodies, as for immuno  
35 suppressive agents, such as cyclosporin, certain structu-  
res, such as macrolides or short peptides.

Furthermore, such non-biological systems could be made more stable, allowing repeated use, higher temperatures and easy sterilisation.

In addition the need for derivatisation of antigens for immunisation purposes is made unnecessary, thereby avoiding the often complicated chemistry and sometimes decreased recognition for the original target molecule (= antigen).

Since the development of the first radioimmunoassay<sup>1</sup>, immunological techniques using labelled reactants have gained an extraordinary prominence in the field of medical research and in clinical diagnosis. In particular, the discovery of monoclonal antibodies<sup>2</sup> and their use in immunoassays has offered novel advantages and more possibilities. Despite the plethora of markers and different procedures<sup>3,4</sup> that have been employed, all the immunological techniques exploit the remarkable affinity and specificity of antibodies. However, antibodies are labile biomolecules which require careful handling and storage. Their production is a time-consuming procedure<sup>5</sup>, including several laborious steps like conjugation of the hapten to a carrier protein, immunisation of animals and isolation of immunoglobulins.

Thus, there was a need for an immunoassay-like technique in which stable and easily prepared highly selective polymers, rather than antibodies are used.

The technique of molecular imprinting has attracted much attention in the last few years<sup>6-8</sup>. Recently, molecular imprinting has been developed to a stage of practical application in enantiomeric separations<sup>11-15</sup>, in particular in the resolution of racemic drugs such as  $\beta$ -blockers<sup>16</sup>.

Furthermore, the technique has been applied to make synthetic enzymes<sup>9,10</sup>.

The technique of molecular imprinting and its special form of non-covalent imprinting as developed by the inventors makes it possible to achieve the above objects.

Briefly, the technique involves polymerisation of functional monomers in the presence of a print molecule (see Scheme 1). Subsequent removal of the print molecule from the rigid polymer results in sites within the polymer  
5 that are complementary to and have an affinity for the original print molecule.

According to the invention there are provided artificial antibodies, which consist of polymers that carry specific binding sites mimicking the properties of anti-  
10 bodies.

There is also provided, according to another aspect of the invention, a method for producing artificial antibodies, in which polymerisable monomers carrying functional groups and crosslinking monomers are polymerised in  
15 the presence of a print molecule and subsequently the print molecule is removed leaving specific binding sites complementary to the print molecule.

The invention also provides for a method for determination of an organic molecule in a fluid sample. According  
20 to this method, a known amount of the organic molecule provided with a label is added to the sample, the sample is contacted with artificial antibodies having specific binding sites for the organic molecule, whereby the labelled and unlabelled organic molecules are competi-  
25 tively bound to the binding sites, and the labelled organic molecule is determined either unbound in the supernatant or bound by the polymer.

There is also provided a method for separation or isolation of an organic molecule from a fluid sample, in  
30 which the sample, labelled or not, is contacted with an excess of artificial antibodies consisting of a polymer having specific sites for the organic molecule, whereby the organic molecule is bound to the binding sites, and optionally the organic molecule is measured bound to the  
35 artificial antibodies or eluted from the antibodies.

The invention also provides for a method of therapy or diagnosis, in which artificial antibodies are administered to a mammal body, which artificial antibodies consist of a biocompatible polymer carrying specific binding sites mimicking the properties of antibodies towards an organic molecule.

In one embodiment of the invention, the polymers are prepared by non-covalent polymerisation.

The polymers constituting the artificial antibodies are preferably built up of polymerisable monomers carrying functional groups and crosslinking monomers. Preferably the polymerisable monomers carrying functional groups are chosen among negatively charged monomers such as methacrylic acid, itaconic acid, basic monomers such as vinylpyridine, vinylimidazole, hydrophobic monomers carrying alkyl chains, monomers allowing  $\pi$ - $\pi$ -interactions, van der Waals forces.

In one embodiment of the invention, polymers are built up of methacrylic acid crosslinked by ethylene glycol dimethacrylate.

If the artificial antibodies are to be used for administration to a mammal body the polymers must be biocompatible. Preferably they must be of the size not more than 5  $\mu$ m or the size of normal biological antibodies, most preferred 10-100 nm.

In preparation of artificial antibodies according to the invention, the polymer is ground to a particle size of normally  $\sim 25 \mu$ m for use in so-called heterogenous assays.

The fines, that is particles with a size of 10-100 or 1000 nm, resulting from the grinding, can be kept in solution or suspension and used for instance in so-called homogenous immunoassays. Such assays are extremely sensitive and can be performed involving e.g. two different antibodies.

Another advantage with the fine particles is that they are more suitable for use in therapy or diagnostics.

Preferably the binding sites are specific for a compound chosen from the group consisting of drugs, metabolites, nucleotides, nucleic acids, carbohydrates, proteins, hormones, toxins, steroids, prostaglandins and leukotrienes.

In one embodiment the binding sites are specific for theophylline or diazepam.

Suitable labels for use in the methods according to the invention are radioligands, enzymes, biotin, steroids, fluorochromes, gold.

The methods according to the invention are preferably used in immunoassays, especially in radioimmunoassays.

The method of therapy or diagnosis according to the invention comprises several different modes of action. For example, it can be used to withdraw an undesired organic molecule from a mammal body, such as a toxin. In another embodiment the artificial antibodies assemble around a cancer cell to indicate the presence of such a cell. In a further embodiment the artificial antibodies are bringing a drug to specific targets, for instance cancer cells.

In one embodiment of treating a mammal body an extra corporal device containing the artificial antibodies is coupled to the body via a shunt in the bloodstream, and the bloodstream is passed through the device.

For the studies the inventors chose two chemically unrelated drugs, theophylline and diazepam, as print molecules. Theophylline, a commonly used drug in the prevention and treatment of asthma, apnea and obstructive lung diseases, has a narrow therapeutic index (56-112  $\mu\text{mol L}^{-1}$  serum) requiring careful monitoring of serum concentrations<sup>17</sup>. Diazepam (e.g. valium) is a member of the benzodiazepine group of drugs widely used as hypnotics, tranquilizers and muscle relaxants<sup>18</sup>. Benzodiazepines are one of the most commonly implicated substances in drug overdose situations and their detection in body fluids is very useful in clinical and forensic toxicology. Current methods for measuring theophylline and benzodiazepines are

based on high-performance liquid chromatography (HPLC)<sup>19-21</sup> and on immunological techniques<sup>22-26</sup>.

The polymers were prepared using methacrylic acid (MAA) as the functional monomer and ethylene glycol dimethacrylate (EDMA) as the crosslinking monomer (Scheme 1). This is a well characterised polymer system that has been used for the preparation of molecular imprints against a number of compounds<sup>12-14,16</sup>. The carboxylic acid function of MAA has been shown to form ionic interactions with amino groups<sup>12</sup> and hydrogen bonds with polar functionalities of the print molecule<sup>14</sup>. The inventors assume that hydrogen bonding is the predominant type of force operating during imprinting and subsequent recognition in the present system. Dipole-dipole and hydrophobic interactions may also contribute.

The solvent compositions giving optimal binding and selectivity were determined for each polymer (see Example 2 and Fig. 1 below). As a general guide<sup>14,27</sup>: i) in a more apolar solvent the substrate binds more strongly to the polymer than in polar solvents, and ii) small amounts of acetic acid can be added to the solvent in order to suppress non-specific binding. The equilibrium dissociation constants ( $K_D$ ) for binding of the drugs to the corresponding polymers were estimated by Scatchard plot analysis using radio-labelled ligands. In both cases, the Scatchard plots were nonlinear and fitted well with two  $K_D$  values, for high and low affinity binding sites. The inventors believe that, as in the case of polyclonal antibodies, the polymers contain a heterogeneous population of sites with different affinities for the print molecule. The  $K_D$  values for the high and low affinity binding sites, calculated with the LIGAND programme (Elsevier-Biosoft), were  $3.46 \times 10^{-7}$  M and  $6.55 \times 10^{-5}$  M (associated with a population of sites of  $0.016 \mu\text{mol g}^{-1}$  and  $1.28 \mu\text{mol g}^{-1}$ , respectively) for theophylline and  $3.76 \times 10^{-8}$  M and  $7.36 \times 10^{-8}$  M ( $0.0071 \mu\text{mol g}^{-1}$  and  $0.51 \mu\text{mol g}^{-1}$ ) for diazepam.

Polymers prepared against theophylline or diazepam were used as antibody-substitutes in the construction of competitive binding for theophylline and diazepam determination in human serum. The method, which we name Molecu-

5 larly Imprinted Sorbent Assay (MIA), relies on the inhibition of binding of radio-labelled ligand by the serum analyte. The amount of radioligand bound to the polymer is inversely related to the concentration of drugs present in the sample. Drug free serum samples spiked with known

10 amounts of theophylline or diazepam were used for establishing the standard calibration curves. Prior to the actual assay, the drug was extracted from the serum by standard protocols used for HPLC-analysis<sup>19-21</sup> (Fig. 1). The MIA for theophylline was linear over the range

15 14-224  $\mu\text{mol L}^{-1}$  which is satisfactory for therapeutic monitoring of the drug. The results for diazepam were linear over the range which is normally used in standard immunoassay techniques for benzodiazepines (0.44-28  $\mu\text{mol L}^{-1}$ ).

20 The specificity of the method was tested by the determination of cross-reactivity of major metabolites and of drugs structurally related to theophylline or diazepam (Table 1).

25

30

35

TABLE 1 Cross-reactivity of various xanthine and uric acid derivatives for binding of <sup>3</sup>H-theophylline (bronchodilator) and various benzodiazepines for binding of <sup>3</sup>H-diazepam (tranquilizer) to artificial antibodies (ArtAb's) and natural antibodies (Ab's).

Theophylline antibodies		Diazepam antibodies	
Competitive ligand	Cross-reaction (%) ArtAb	Competitive ligand	Cross-reaction (%) ArtAb
Theophylline (1,3-dimethyl-xanthine)	100	Diazepam (e.g. valium)	100
3-Methylxanthin	7	Alprazolam	40
Xanthine	<1	Demethyldiazepam	27
Hypoxanthine	<1		32
7-(β-Hydroxyethyl)-1,3-dimethylxanthine	<1	Clonazepam	9
Caffeine (1,3,7-trimethylxanthine)	<1	Lorazepam	4
Theobromine (3,7-dimethylxanthine)	<1	Chlordiazepoxid	2
Uric acid	<1		<1
1-Methyluric acid	<1		
1,3-Dimethyluric acid	<1		

The ligands were added to drug free serum and assayed as described in Fig. 1. Cross-reactivities are expressed as the molar ratio of theophylline and diazepam, respectively, to ligand giving 50% inhibition of radioligand binding to polymer.


\* Data from ref 22.

\*\* Data from ref 24.




The MIA method for theophylline (1,3-dimethylxanthine) appears to be highly specific since from all the compounds tested only 3-methylxanthine showed some cross-reactivity.

In the case of the diazepam assay several other  
5 benzodiazepines showed significant cross-reactivity. This was, however, expected because benzodiazepines are very similar in structure, as seen below:



10

		R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	
15	Diazepam	Cl	Me	O	H	H	
	Desmethyldiazepam	Cl	H	O	H	H	
	Clonazepam	NO <sub>2</sub>	H	O	H	Cl	
20	Lorazepam	Cl	H	O	OH	Cl	
	Alprazolam	Cl				H	H

25

and even antibodies have difficulty in distinguishing between them<sup>25,26</sup> (Table 1).

The ability of the MIA method for accurate measurement of theophylline was evaluated by analysing 32 patient  
30 serum samples. The sample were also analysed with the Enzyme-Multiplied Immunoassay Technique (EMIT)<sup>28</sup> and the comparison of the results obtained showed excellent correlation between the two methods (Fig. 1). Furthermore, the reliability of the assay was determined by measurement of  
35 theophylline samples of known concentration (three clinical significant concentrations; eleven repetitions; coefficient of variation  $\leq 6.5\%$ ).

The results presented here demonstrate, for the first time, the ability to use chemically prepared macromolecules with preselected specificity, instead of the traditional biomolecules, as receptors in competitive binding assays. A great advantage of molecularly imprinted polymers is their simple and rapid (two to three days) preparation and their remarkable stability. They can be stored in the dry state, even at elevated temperatures, for several years without loss of recognition capabilities<sup>27</sup>. In addition, the potential to reuse the polymers may prove valuable. Furthermore, by analogy to immunoaffinity chromatography, molecularly imprinted polymers could be useful for the separation and isolation of different compounds. Apart from the practical importance of the described preparations, structural studies on the interactions of drugs with their artificial receptors could yield valuable insight into the nature of molecular recognition phenomena<sup>29-31</sup>.

Molecular imprints may be obtained against functionality complementary to the monomer<sup>14,27</sup>. There is a potential for molecularly imprinted artificial antibodies in the analysis of many other drugs, metabolites, hormones, toxins, etc.

It is also noteworthy that molecularly imprinted polymers provide a potential alternative to the use of laboratory animals for the production of antibodies. Preliminary data from similar studies with an emphasis on recognition in aqueous systems using other compounds such as opiates and biologically active peptides, indicate that this technique promises to become widely useful.

The invention is described more in detail with reference to the following examples and the accompanying drawing.

Figure 1 shows a comparison of the competitive binding assays Enzyme-Multiplied Immunoassay Technique (EMIT)<sup>28</sup> and MIA for determination of serum concentration of theophylline in patient samples (n=32).

Example 1

## Preparation of molecularly imprinted polymers

The preparation follows the reaction of Scheme 1.

- A) The functional monomer, methacrylic acid (MAA,1), is  
 5 mixed with the print molecule, here theophylline (2), and  
 ethylene glycol dimethacrylate (EDMA), the crosslinking  
 monomer, in a suitable solvent. MAA is selected for its  
 ability to form hydrogen bonds with a variety of chemical  
 functionalities of the print molecule.
- 10 B) The polymerisation reaction is started with the addi-  
 tion of initiator (AIBN) and a rigid insoluble polymer is  
 formed. "Imprints", which are complementary in both shape  
 and chemical functionality to the print molecule, are now  
 present within the polymeric network.
- 15 C) The print molecule is removed by extraction.

The wavy lines in Scheme 1 represent an idealised  
 polymer structure but do not take into account the  
 accessibility of the substrate to the recognition site in  
 the macroporous polymer structure.

20 METHODSAnti-theophylline polymer

- To a glass bottle were added chloroform (250 ml),  
 theophylline (4.7 g), MAA (9 g), EDMA (93,5 g) and 2,2'-  
 -azobis(2-methylpropionitrile) (AIBN, initiator, 1.2 g).
- 25 The mixture was degassed under vacuum in a sonicating  
 waterbath and sparged with nitrogen for 5 min. The poly-  
 merisation reaction took place at 60°C for 24 h. The bulk  
 polymer was grounded in a mechanical mortar and wet sieved  
 (water) through a 25 µm sieve. The fines were removed by  
 30 repeated settling in acetonitrile. The print molecule  
 (theophylline) was extracted by extensive washing of the  
 particles with methanol-acetic acid (9/1, v/v). Finally,  
 the polymer particles were dried under vacuum and stored  
 in a desiccator.

Anti-diazepam polymer

Diazepam (1.27 g) was mixed with MAA (2.26 g), EDMA (26.1 g) and AIBN (0.5 g) in chloroform (39 ml). The polymerisation mixture was degassed under vacuum in a sonicating water-bath, sparged with nitrogen and then polymerised under UV (366 nm) at 4°C for 16 h. The resulting polymer was then treated as described above.

Example 2

A comparison of the competitive binding assays  
 10 Enzyme-Multiplied Immunoassay Technique (EMIT)<sup>28</sup> and MIA for determination of serum concentration of theophylline in patient samples (n=32) was performed. EMIT reagents were supplied by the manufacturer (SYVA, Palo Alto, USA). All enzyme immunoassays were performed at the department  
 15 of Clinical Pharmacology, University Hospital, Lund, Sweden, according to the method of the manufacturer. The result is shown in Fig. 1:

Slope: 0.99, Intercept: 1.50  $\mu\text{mol L}^{-1}$ , correlation coefficient: 0.98.

20 METHODS

The assay conditions were established by applying similar protocols as is standard for the optimisation of immunoassays using antibodies<sup>32</sup>. 40  $\mu\text{l}$  of each sample was mixed with 40  $\mu\text{l}$  of HCl (0.2 M) and extracted with 1 ml of  
 25 dichloromethaneisopropanol (4/1, v/v). The organic layer was evaporated at 40°C under a stream of nitrogen. The residue was redissolved in 100  $\mu\text{l}$  of acetonitrile-acetic acid (99/1, v/v) containing [<sup>3</sup>H]-theophylline (5 ng, 18.6 Ci  $\text{mmol}^{-1}$ ). Polymer imprinted against theophylline  
 30 was then added (12.5 mg of polymer in 0.9 ml of the same solvent) and the mixture was incubated for 15 h at room temperature. The binding equilibrium was reached after 8 h, 80 and 90% of the binding occurred within 3 and 5 h. After centrifugation, the unbound [<sup>3</sup>H]-theophylline in  
 35 200  $\mu\text{l}$  of the supernatant was measured by liquid scintillation counting. The calibration graph was linear over the range 14-224  $\mu\text{mol L}^{-1}$  (correlation coefficient = 0.999)

and the detection limit of the assay was found to be  $3.5 \mu\text{mol L}^{-1}$ . The diazepam assay, performed in a similar manner using 5 mg of polymer in toluene-heptane (4:1; v/v), was linear from 0.44 to  $28 \mu\text{mol L}^{-1}$  (correlation coefficient = 0,991) with a detection limit of  $0.2 \mu\text{mol L}^{-1}$ .

10

15

20

25

30


35

### References


1. Yalow, R. S. & Berson, S. A. *Nature* 184, 1648-1649 (1959).
2. Köhler, G. & Milstein, C. *Nature* 256, 495-497 (1975).
- 5 3. Oellerich, M. J. *Clin. Chem. Clin. Biochem.* 22, 895-904 (1984).
4. Gosling, J. P. *Clin. Chem.* 36, 1408-1427 (1990).
5. Kurstak, E. in *Enzyme Immunodiagnosis* (ed Kurstak, E.) 5-11 (Academic Press, London, 1986).
- 10 6. Ekberg, B. & Mosbach, K. *Trends Biotechnol.* 7, 92-96 (1989).
7. Wulff, G. *Amer. Chem. Soc. Symp. Series* 308, 186-230 (1986).
8. Shea, K. J. & Sasaki, D. Y. *J. Am. Chem. Soc.* 113, 4109-4120 (1991).
- 15 9. Robinson, D. K. and Mosbach, K. J. *Chem. Soc. Chem. Commun.* 14, 969-970 (1989).
10. US patent No. 5,110,833 to Klaus Mosbach.
11. Sellergren, B., Ekberg, B. & Mosbach, K. J. *Chromatogr.* 347, 1-10 (1985).
- 20 12. Sellergren, B., Lepistö, M. & Mosbach, K. J. *Am. Chem. Soc.* 110, 5853-5860 (1988).
13. O'Shannessy, D. J., Ekberg, B., Andersson, L. I. & Mosbach, K. J. *Chromatogr.* 470, 391-399 (1989).
- 25 14. Andersson, L. I. & Mosbach, K. J. *Chromatogr.* 516, 313-322 (1990).
15. Wulff, G. & Minarik, M. J. *Liq. Chromatogr.* 13, 2987-3000 (1990).
16. Fischer, L., Müller, R., Ekberg, B. & Mosbach, K. J. *Am. Chem. Soc.* 113, 9358-9360 (1991).
- 30 17. Hendeles, L., Weinberger, M. & Johnson, G. *Clin. Pharmacokinetics* 3, 294-312 (1978).
18. Harvey, S. L. in *The Pharmacological Basis of Therapeutics* (eds Gilman, A. G., Goodman, L. S., Rail, T. W. & Murad, F.) 339-351 (Marcel Dekker, Inc., New York, 1985).
- 35

19. Meffin, P. J. & Miners, J. O. in Progress in Drug Metabolism (eds Bridges, J. W. & Chasseaud, L. F.) Vol. 4, 261-307 (J. Wiley, London, 1980).
20. Peng, G. W., Gadalla, M. A. F. & Chiou, W. L. Clin. Chem. 24, 357-361 (1978).
21. Mura, P., Piriou, A., Fraillon, P., Papet, Y. & Reiss, D. J. Chromatogr. 416, 303-310 (1987).
22. Castro, A., Ibanez, J., Voight, W., Noto, T. & Malkus, H. Clin. Chem. 24, 944-946 (1978).
23. Chang, J., Gotcher, S. & Gushaw, J. B. Clin. Chem. 26, 361-367 (1982).
24. Poncelet, S. M., Limet, J. N., Noel, J. P., Kayaert, M. C., Galanti, L. & Collet-Cassart, D. J. Immunoassay, 11, 77-88 (1990).
25. Baselt, R. C. in Advances in Analytical Toxicology (ed Baselt, R. C.) Vol. 1, 81-123 (Biomedical Publications, Foster City, CA, 1984).
26. Aitunkaya, D. & Smith, R. N. Forensic. Sci. Int., 39, 23-37 (1988).
27. Andersson, L. I. thesis, Lund Univ. (1991).
28. Dietzler, D. N., Waldner, N., Tieber, V. L., McDonald, J. M., Smith, C. H., Ladenson, J. H. & Leckie, M. P. Clin. Chim. Acta 101, 163-181 (1980).
29. Cram, D. J. Nature 356, 29-36 (1992).
30. Rebek, J. Jr. Angew. Chem. Int. Ed. Engl. 29, 245-255 (1990).
31. Desiongchamps, G., Galán, A., de Mendoza, J. & Rebek, J. Jr. Angew. Chem. Int. Ed. Engl. 31, 61-63 (1992).
32. Tijssen, P. Laboratory Techniques in Biochemistry and Molecular Biology, Practice and Theory of Enzyme Immunoassays 5th printing (Elsevier Publishers B.V., Amsterdam, 1988).


## SCHEME 1



b  
polymerization



c  
extraction





## CLAIMS

1. Artificial antibodies, characterised  
5 in that they consist of polymers that carry specific binding sites mimicking the properties of antibodies.

2. Artificial antibodies according to claim 1,  
characterised in that the polymers are prepared by polymerisation of polymerisable monomers carrying  
10 functional groups and crosslinking monomers.

3. Artificial antibodies according to claim 1 or 2,  
characterised in that the polymers are prepared by non-covalent polymerisation.

4. Artificial antibodies according to claim 2 or 3,  
15 characterised in that the polymerisable monomers carrying functional groups are chosen among negatively charged monomers such as methacrylic acid, itaconic acid, basic monomers such as vinylpyridine, vinylimidazole, hydrophobic monomers carrying alkyl  
20 chains, monomers allowing  $\pi$ - $\pi$ -interactions, van der Waals forces.

5. Artificial antibodies according to any one of the preceding claims, characterised in that the polymers are built up of methacrylic acid cross-  
25 linked by ethylene glycol dimethacrylate.

6. Artificial antibodies according to any one of the preceding claims, characterised in that the polymers are biocompatible.

7. Artificial antibodies according to claim 6,  
30 characterised in that they are of a size of not more than 5  $\mu$ m, preferably 10-100 nm.

8. Artificial antibodies according to any one of the preceding claims, characterised in that the binding sites are specific for a compound chosen from the  
35 group consisting of drugs, metabolites, nucleotides, nucleic acids, carbohydrates, proteins, hormones, toxins, steroids, prostaglandins and leukotrienes.

9. Artificial antibodies according to any one of the preceding claims, characterised in that the binding sites are specific for theophylline.

10. Artificial antibodies according to any one of claims 1-8, characterised in that the binding sites are specific for diazepam.

11. A method for producing artificial antibodies, characterised in that polymerisable monomers carrying functional groups and crosslinking monomers are polymerised in the presence of a print molecule and subsequently the print molecule is removed, leaving specific binding sites complementary to the print molecules.

12. A method according to claim 11, characterised in that the polymerisation is a non-covalent polymerisation.

13. A method according to claim 11 or 12, characterised in that the polymerisable monomers are chosen among negatively charged monomers such as methacrylic acid, itaconic acid, basic monomers such as vinylpyridine, vinylimidazole, hydrophobic monomers carrying alkyl chains, monomers allowing  $\pi$ - $\pi$ -interactions, van der Waals forces.

14. A method according to any one of claims 11-13, characterised in that the polymerisable monomers are methacrylic acid and the crosslinking monomers are ethylene glycol dimethacrylate.

15. A method according to any one of claims 11-14, characterised in that the polymers are made into a size of not more than 5  $\mu$ m, preferably 10-100 nm.

16. A method according to any one of claims 11-15, characterised in that the print molecule is chosen from the group consisting of drugs, metabolites, nucleotides, nucleic acids, carbohydrates, proteins, hormones, toxins, steroids, prostaglandins and leukotrienes.

17. A method according to any one of claims 11-16, characterised in that the print molecule is theophylline.

18. A method according to any one of claims 11-16, characterised in that the print molecule is diazepam.

19. A method for determination of an organic molecule  
5 in a fluid sample, characterised in that a known amount of the organic molecule provided with a label is added to the sample, the sample is contacted with artificial antibodies as claimed in any one of claims 1-9 having specific binding sites for the organic molecule,  
10 whereby the labelled and unlabelled organic molecules are competitively bound to the binding sites, and the labelled organic molecule is determined either unbound in the supernatant or bound by the polymer.

20. A method according to claim 19, characterised in that the label is chosen from the group  
15 consisting of radioligands, enzymes, biotin, steroids, fluorochromes, electrochemiluminescent compounds, gold.

21. Use of the method according to claim 19 or 20 in heterogenous or homogenous immunoassays.

22. Use according to claim 21 in homogenous immunoassays, whereby the artificial antibodies are of a size of not more than 5  $\mu\text{m}$ , preferably 10-100 nm.

23. A method for separation or isolation of an organic molecule from a fluid sample, characterised in that the sample, labelled or not, is  
25 contacted with an excess of artificial antibodies as claimed in any one of claims 1-9 having specific sites for the organic molecule, whereby the organic molecule is bound to the binding sites, and optionally the organic molecule is measured bound to the artificial antibodies or  
30 eluted from the antibodies.

24. A method of therapy or diagnosis, characterised in administration of artificial antibodies to a mammal body, which artificial antibodies consist of a  
35 biocompatible polymer carrying specific binding sites mimicking the properties of antibodies towards an organic molecule.

25. A method according to claim 24, c h a r a c -  
t e r i s e d in that an extraçorporal device containing  
the artificial antibodies is coupled to the body via a  
shunt in the bloodstream, and the bloodstream is passed  
5 through the device.

26. A method according to claim 23 or 24, c h a -  
r a c t e r i s e d in that the artificial anitbodies are  
of a size of not more than 5  $\mu\text{m}$ , preferably 10-100 nm.

10

15

20

25

30


35

## ABSTRACT

Artificial antibodies or antibody mimics are described. They consist of polymers that carry specific binding sites mimicking the properties of antibodies. There is also described a method for producing artificial antibodies, in which polymerisable monomers carrying functional groups and crosslinking monomers are polymerised in the presence of a print molecule and subsequently the print molecule is removed leaving specific binding sites complementary to the print molecules.

There are also described methods for determination and isolation of organic molecules using the artificial antibodies as well as therapeutic and diagnostic methods using these antibodies.

FIG. 1



**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR UTILITY PATENT APPLICATION**

Attorney's Docket No.

003300-357

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I BELIEVE I AM THE ORIGINAL, FIRST AND SOLE INVENTOR (if only one name is listed below) OR AN ORIGINAL, FIRST AND JOINT INVENTOR (if more than one name is listed below) OF THE SUBJECT MATTER WHICH IS CLAIMED AND FOR WHICH A PATENT IS SOUGHT ON THE INVENTION ENTITLED:

ARTIFICIAL ANTIBODIES, METHOD OF PRODUCING THE SAME AND USE THEREOF

the specification of which

(check one)

☐

is attached hereto;

☒

was filed on May 11, 1995 as

Application No. 08/433,514

was amended on May 11, 1995;  
(if applicable)

and corresponds to PCT/SE93/00960

filed 11 November 1993

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE;

I ACKNOWLEDGE THE DUTY TO DISCLOSE TO THE OFFICE ALL INFORMATION KNOWN TO ME TO BE MATERIAL TO PATENTABILITY AS DEFINED IN TITLE 37, CODE OF FEDERAL REGULATIONS, Sec. 1.56 (as amended effective March 16, 1992);

I do not know and do not believe the said invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application; that said invention was not in public use or on sale in the United States of America more than one year prior to said application; that said invention has not been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than twelve months prior to said application;

I hereby claim foreign priority benefits under Title 35, United States Code Sec. 119 and/or Sec. 365 of any foreign application(s) for patent or inventor's certificate as indicated below and have also identified below any foreign application for patent or inventor's certificate on this invention having a filing date before that of the application(s) on which priority is claimed:

MAILED  
DEC 12/7/95

## COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney's Docket No.

003300-357

COUNTRY/INTERNATIONAL	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
SWEDEN	9203435-4	11 NOVEMBER 1992	YES <u>X</u> NO <u>  </u>
			YES <u>  </u> NO <u>  </u>

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Samuel C. Miller, III	27,360	Robert M. Schulman	31,196
Peter H. Smolka	15,913	Ralph L. Freeland, Jr.	16,110	William C. Rowland	30,888
Robert S. Swecker	19,885	Robert G. Mukai	28,531	T. Gene Dillahunty	25,423
Platon N. Mandros	22,124	George A. Hovanec, Jr.	28,223	Anthony W. Shaw	30,104
Benton S. Duffett, Jr.	22,030	James A. LaBarre	28,632	Patrick C. Keane	32,858
Joseph R. Magnone	24,239	E. Joseph Gess	28,510	Bruce J. Boggs, Jr.	32,344
Norman H. Stepno	22,716	R. Danny Huntington	27,903	William H. Benz	25,952
Ronald L. Grudziecki	24,970	Eric H. Weisblatt	30,505	Peter K. Skiff	31,917
Frederick G. Michaud, Jr.	26,003	James W. Peterson	26,057	Richard J. McGrath	29,195
Alan E. Kopecki	25,813	Teresa Stanek Rea	30,427	Matthew L. Schneider	32,814
Regis E. Slutter	26,999	Robert E. Krebs	25,885	Michael G. Savage	32,596

and: NONE

Address all correspondence to:

**BENTON S. DUFFETT, JR.**  
 Burns, Doane, Swecker & Mathis  
 P.O. Box 1404  
 Alexandria, Virginia 22313-1404

Address all telephone calls to: BENTON S. DUFFETT, JR. at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	SIGNATURE	DATE
Klaus Mosbach		
RESIDENCE	CITIZENSHIP	
Furulund, Sweden	Sweden	
POST OFFICE ADDRESS		
Lackalänga 31, S-244 94 Furulund, Sweden		
FULL NAME OF SECOND JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Georg Vlatakis		
RESIDENCE	CITIZENSHIP	
Heraklion, Crete, Greece	Greece	
POST OFFICE ADDRESS		
Foundation for Research & Technology, Institute of Molecular Biology and Biotechnology, GR-711 70 Heraklion, Crete, Greece		
FULL NAME OF THIRD JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Lars I. Andersson		
RESIDENCE	CITIZENSHIP	
Eslöv, Sweden	Sweden	
POST OFFICE ADDRESS		
Skogsvägen 45, S-241 31 Eslöv, Sweden		
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Ralf Müller	<i>R. Müller</i>	24/11/95
RESIDENCE	CITIZENSHIP	
Henstedt-Ulzburg, Germany	Germany	
POST OFFICE ADDRESS		
Gorch-Foch Strasse 25, D-2359 Henstedt-Ulzburg 3, Germany		



**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR UTILITY PATENT APPLICATION**

Attorney's Docket No.

003300-357

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I BELIEVE I AM THE ORIGINAL, FIRST AND SOLE INVENTOR (if only one name is listed below) OR AN ORIGINAL, FIRST AND JOINT INVENTOR (if more than one name is listed below) OF THE SUBJECT MATTER WHICH IS CLAIMED AND FOR WHICH A PATENT IS SOUGHT ON THE INVENTION ENTITLED:

ARTIFICIAL ANTIBODIES, METHOD OF PRODUCING THE SAME AND USE THEREOF

the specification of which

(check one)

☐

is attached hereto;

☒

was filed on May 11, 1995 as

Application No. 08/433,514

was amended on May 11, 1995;  
(if applicable)

and corresponds to PCT/SE93/00960

filed 11 November 1993

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE;

I ACKNOWLEDGE THE DUTY TO DISCLOSE TO THE OFFICE ALL INFORMATION KNOWN TO ME TO BE MATERIAL TO PATENTABILITY AS DEFINED IN TITLE 37, CODE OF FEDERAL REGULATIONS, Sec. 1.56 (as amended effective March 16, 1992);

I do not know and do not believe the said invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application; that said invention was not in public use or on sale in the United States of America more than one year prior to said application; that said invention has not been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than twelve months prior to said application;

I hereby claim foreign priority benefits under Title 35, United States Code Sec. 119 and/or Sec. 365 of any foreign application(s) for patent or inventor's certificate as indicated below and have also identified below any foreign application for patent or inventor's certificate on this invention having a filing date before that of the application(s) on which priority is claimed:

## COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney's Docket No.

003300-357

COUNTRY/INTERNATIONAL	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
SWEDEN	9203435-4	11 NOVEMBER 1992	YES <u>X</u> NO <u>  </u>
			YES <u>  </u> NO <u>  </u>

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Samuel C. Miller, III	27,360	Robert M. Schulman	31,196
Peter H. Smolka	15,913	Ralph L. Freeland, Jr.	16,110	William C. Rowland	30,888
Robert S. Swecker	19,885	Robert G. Mukai	28,531	T. Gene Dillahunt	25,423
Platon N. Mandros	22,124	George A. Hovanec, Jr.	28,223	Anthony W. Shaw	30,104
Benton S. Duffett, Jr.	22,030	James A. LaBarre	28,632	Patrick C. Keane	32,858
Joseph R. Magnone	24,239	E. Joseph Gess	28,510	Bruce J. Boggs, Jr.	32,344
Norman H. Stepno	22,716	R. Danny Huntington	27,903	William H. Benz	25,952
Ronald L. Grudziecki	24,970	Eric H. Weisblatt	30,505	Peter K. Skiff	31,917
Frederick G. Michaud, Jr.	26,003	James W. Peterson	26,057	Richard J. McGrath	29,195
Alan E. Kopecki	25,813	Teresa Stanek Rea	30,427	Matthew L. Schneider	32,814
Regis E. Slutter	26,999	Robert E. Krebs	25,885	Michael G. Savage	32,596


and: NONE

Address all correspondence to:

**BENTON S. DUFFETT, JR.**  
Burns, Doane, Swecker & Mathis  
P.O. Box 1404  
Alexandria, Virginia 22313-1404

Address all telephone calls to: BENTON S. DUFFETT, JR. at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	SIGNATURE	DATE
Klaus Mosbach		
RESIDENCE	CITIZENSHIP	
Furulund, Sweden	Sweden	
POST OFFICE ADDRESS		
Lackalunga 31, S-244 94 Furulund, Sweden		
FULL NAME OF SECOND JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Georg Vlatakis		31-10-95
RESIDENCE	CITIZENSHIP	
Heraklion, Crete, Greece	Greece	
POST OFFICE ADDRESS		
Foundation for Research & Technology, Institute of Molecular Biology and Biotechnology, GR-711 70 Heraklion, Crete, Greece		
FULL NAME OF THIRD JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Lars I. Andersson		
RESIDENCE	CITIZENSHIP	
Eslöv, Sweden	Sweden	
POST OFFICE ADDRESS		
Skogsvägen 45, S-241 31 Eslöv, Sweden		
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Ralf Müller		
RESIDENCE	CITIZENSHIP	
Henstedt-Ulzburg, Germany	Germany	
POST OFFICE ADDRESS		
Gorch-Foch Strasse 25, D-2359 Henstedt-Ulzburg 3, Germany		

**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR UTILITY PATENT APPLICATION**

Attorney's Docket No.

003300-357

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I BELIEVE I AM THE ORIGINAL, FIRST AND SOLE INVENTOR (if only one name is listed below) OR AN ORIGINAL, FIRST AND JOINT INVENTOR (if more than one name is listed below) OF THE SUBJECT MATTER WHICH IS CLAIMED AND FOR WHICH A PATENT IS SOUGHT ON THE INVENTION ENTITLED:

ARTIFICIAL ANTIBODIES, METHOD OF PRODUCING THE SAME AND USE THEREOF

the specification of which

(check one)

☐

is attached hereto;

☒

was filed on May 11, 1995 as

Application No. 08/433,514

was amended on May 11, 1995;

(if applicable)

and corresponds to PCT/SE93/00960

filed 11 November 1993

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE;

I ACKNOWLEDGE THE DUTY TO DISCLOSE TO THE OFFICE ALL INFORMATION KNOWN TO ME TO BE MATERIAL TO PATENTABILITY AS DEFINED IN TITLE 37, CODE OF FEDERAL REGULATIONS, Sec. 1.56 (as amended effective March 16, 1992);

I do not know and do not believe the said invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application; that said invention was not in public use or on sale in the United States of America more than one year prior to said application; that said invention has not been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than twelve months prior to said application;

I hereby claim foreign priority benefits under Title 35, United States Code Sec. 119 and/or Sec. 365 of any foreign application(s) for patent or inventor's certificate as indicated below and have also identified below any foreign application for patent or inventor's certificate on this invention having a filing date before that of the application(s) on which priority is claimed:

003300-357

## COMBINED DECLARATION AND POWER OF ATTORNEY

COUNTRY/INTERNATIONAL	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
SWEDEN	9203435-4	11 NOVEMBER 1992	YES <u>X</u> NO <u>  </u>
			YES <u>  </u> NO <u>  </u>

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Samuel C. Miller, III	27,360	Robert M. Schulman	31,196
Peter H. Smolka	15,913	Ralph L. Freeland, Jr.	16,110	William C. Rowland	30,888
Robert S. Swecker	19,885	Robert G. Mukai	28,531	T. Gene Dillahunt	25,423
Platon N. Mandros	22,124	George A. Hovanec, Jr.	28,223	Anthony W. Shaw	30,104
Benton S. Duffett, Jr.	22,030	James A. LaBarre	28,632	Patrick C. Keane	32,858
Joseph R. Magnone	24,239	E. Joseph Gess	28,510	Bruce J. Boggs, Jr.	32,344
Norman H. Stepno	22,716	R. Danny Huntington	27,903	William H. Benz	25,952
Ronald L. Grudziecki	24,970	Eric H. Weisblatt	30,505	Peter K. Skiff	31,917
Frederick G. Michaud, Jr.	26,003	James W. Peterson	26,057	Richard J. McGrath	29,195
Alan E. Kopecki	25,813	Teresa Stanek Rea	30,427	Matthew L. Schneider	32,814
Regis E. Slutter	26,999	Robert E. Krebs	25,885	Michael G. Savage	32,596

and: NONE

Address all correspondence to: **BENTON S. DUFFETT, JR.**  
**Burns, Doane, Swecker & Mathis**  
 P.O. Box 1404  
 Alexandria, Virginia 22313-1404

Address all telephone calls to: BENTON S. DUFFETT, JR. at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	SIGNATURE	DATE
Klaus Mosbach		
RESIDENCE	CITIZENSHIP	
Furulund, Sweden	Sweden	
POST OFFICE ADDRESS		
Lackalänga 31, S-244 94 Furulund, Sweden		
FULL NAME OF SECOND JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Georg Vlatakis		
RESIDENCE	CITIZENSHIP	
Heraklion, Crete, Greece	Greece	
POST OFFICE ADDRESS		
Foundation for Research & Technology, Institute of Molecular Biology and Biotechnology, GR-711 70 Heraklion, Crete, Greece		
FULL NAME OF THIRD JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Lars I. Andersson	<i>Lars I. Andersson</i>	30/10/1995
RESIDENCE	CITIZENSHIP	
Eslöv, Sweden	Sweden	
POST OFFICE ADDRESS		
Skogsvägen 45, S-241 31 Eslöv, Sweden		
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Ralf Müller		
RESIDENCE	CITIZENSHIP	
Henstedt-Ulzburg, Germany	Germany	
POST OFFICE ADDRESS		
Gorch-Foch Strasse 25, D-2359 Henstedt-Ulzburg 3, Germany		

**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR UTILITY PATENT APPLICATION**

Attorney's Docket No.

003300-357

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I BELIEVE I AM THE ORIGINAL, FIRST AND SOLE INVENTOR (if only one name is listed below) OR AN ORIGINAL, FIRST AND JOINT INVENTOR (if more than one name is listed below) OF THE SUBJECT MATTER WHICH IS CLAIMED AND FOR WHICH A PATENT IS SOUGHT ON THE INVENTION ENTITLED:

ARTIFICIAL ANTIBODIES. METHOD OF PRODUCING THE SAME AND USE THEREOF

the specification of which

(check one)

☐

is attached hereto;

☒

was filed on May 11, 1995 as

Application No. 08/433,514

was amended on May 11, 1995 ;

(if applicable)

and corresponds to PCT/SE93/00960

filed 11 November 1993

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE;

I ACKNOWLEDGE THE DUTY TO DISCLOSE TO THE OFFICE ALL INFORMATION KNOWN TO ME TO BE MATERIAL TO PATENTABILITY AS DEFINED IN TITLE 37, CODE OF FEDERAL REGULATIONS, Sec. 1.56 (as amended effective March 16, 1992);

I do not know and do not believe the said invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application; that said invention was not in public use or on sale in the United States of America more than one year prior to said application; that said invention has not been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than twelve months prior to said application;

I hereby claim foreign priority benefits under Title 35, United States Code Sec. 119 and/or Sec. 365 of any foreign application(s) for patent or inventor's certificate as indicated below and have also identified below any foreign application for patent or inventor's certificate on this invention having a filing date before that of the application(s) on which priority is claimed:

## COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney's Docket No.

003300-357

COUNTRY/INTERNATIONAL	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
SWEDEN	9203435-4	11 NOVEMBER 1992	YES <u>X</u> NO <u>  </u>
			YES <u>  </u> NO <u>  </u>

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Samuel C. Miller, III	27,360	Robert M. Schulman	31,196
Peter H. Smolka	15,913	Ralph L. Freeland, Jr.	16,110	William C. Rowland	30,888
Robert S. Swecker	19,885	Robert G. Mukai	28,531	T. Gene Dillahunty	25,423
Platon N. Mandros	22,124	George A. Hovanec, Jr.	28,223	Anthony W. Shaw	30,104
Benton S. Duffett, Jr.	22,030	James A. LaBarre	28,632	Patrick C. Keane	32,858
Joseph R. Magnone	24,239	E. Joseph Gess	28,510	Bruce J. Boggs, Jr.	32,344
Norman H. Stepno	22,716	R. Danny Huntington	27,903	William H. Benz	25,952
Ronald L. Grudziecki	24,970	Eric H. Weisblatt	30,505	Peter K. Skiff	31,917
Frederick G. Michaud, Jr.	26,003	James W. Peterson	26,057	Richard J. McGrath	29,195
Alan E. Kopecki	25,813	Teresa Stanek Rea	30,427	Matthew L. Schneider	32,814
Regis E. Slutter	26,999	Robert E. Krebs	25,885	Michael G. Savage	32,596

and: NONE

Address all correspondence to:

**BENTON S. DUFFETT, JR.**  
Burns, Doane, Swecker & Mathis  
P.O. Box 1404  
Alexandria, Virginia 22313-1404

Address all telephone calls to: BENTON S. DUFFETT, JR. at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	SIGNATURE	DATE
Klaus Mosbach	<i>Klaus Mosbach</i>	Oct. 24, 1995
RESIDENCE	CITIZENSHIP	
Furulund, Sweden	Sweden	
POST OFFICE ADDRESS		
Lackalänga 31, S-244 94 Furulund, Sweden		
FULL NAME OF SECOND JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Georg Vlatakis		
RESIDENCE	CITIZENSHIP	
Heraklion, Crete, Greece	Greece	
POST OFFICE ADDRESS		
Foundation for Research & Technology, Institute of Molecular Biology and Biotechnology, GR-711 70 Heraklion, Crete, Greece		
FULL NAME OF THIRD JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Lars I. Andersson		
RESIDENCE	CITIZENSHIP	
Eslöv, Sweden	Sweden	
POST OFFICE ADDRESS		
Skogsvägen 45, S-241 31 Eslöv, Sweden		
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Ralf Müller		
RESIDENCE	CITIZENSHIP	
Henstedt-Ulzburg, Germany	Germany	
POST OFFICE ADDRESS		
Gorch-Foch Strasse 25, D-2359 Henstedt-Ulzburg 3, Germany		